BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HLX43 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HLX43\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06839066-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:HLX43: Phase 2 readout est. (NCT06839066)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Study to Evaluate HLX43 in 
 Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Into
 lerance to Second-line Therapy\nEstimated primary completion: 22 November 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06839066
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115642-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43: Phase 1 readout est. (NCT06115642)
DESCRIPTION:HLX43\, phase 1.\nStudy: A Phase I Study to Evaluate the Safety
 \, Tolerability\, and PK of HLX43 in Advanced/Metastatic Solid Tumors\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hlx43#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06115642
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106892-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43: Phase 2 readout est. (NCT07106892)
DESCRIPTION:HLX43\, phase 2.\nStudy: Phase II\, Open-label\, Multicenter St
 udy to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su
 bjects With Advanced Colorectal Cancer\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07106
 892
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459738-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43: Phase 2 readout est. (NCT07459738)
DESCRIPTION:HLX43\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy: A
  Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients W
 ith Hormone Receptor Positive\, HER2 Negative Locally Advanced or Metastat
 ic Breast Cancer\nEstimated primary completion: 30 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07459738
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769152-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HLX43: Phase 2 readout est. (NCT06769152)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Clinical Study to Evaluate 
 the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advance
 d Gynecological Malignant Tumors\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769152
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487519-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:HLX43: Phase 2 readout est. (NCT07487519)
DESCRIPTION:HLX43\, phase 2.\nStudy: Phase II Study of HLX43 Monotherapy or
  Combined With Immune Checkpoint Inhibitors in Patients With Locally Advan
 ced\, Recurrent\, or Metastatic Triple-negative Breast Cancer.\nEstimated 
 primary completion: 15 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/hlx43#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07487519
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:HLX43: Phase 2 readout est. (NCT07253142)
DESCRIPTION:HLX43\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subj
 ects With Advanced Lung Cancer\nEstimated primary completion: 18 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07253142
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358585-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:HLX43: Phase 1/2 readout est. (NCT07358585)
DESCRIPTION:HLX43\, phase 1/2.\nStudy: A Phase Ib/II Study to Evaluate HLX4
 3 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastat
 ic Colorectal Cancer\nEstimated primary completion: 28 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07358585
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115485-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HLX43: Phase 2 readout est. (NCT07115485)
DESCRIPTION:HLX43\, phase 2.\nStudy: Phase II\, Open-label\, Multicenter St
 udy to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su
 bjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma\n
 Estimated primary completion: 30 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/hlx43#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07115485
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857279-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:HLX43: Phase 2 readout est. (NCT06857279)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Clinical Study to Evaluate 
 HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell
  Carcinoma\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06857279
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301229-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:HLX43: Phase 2 readout est. (NCT07301229)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Clinical Study to Evaluate 
 HLX43 in Subjects With Advanced Pancreatic Cancer\nEstimated primary compl
 etion: 21 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/hlx43#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07301229
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06907615-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:HLX43: Phase 2 readout est. (NCT06907615)
DESCRIPTION:HLX43\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cel
 l Lung Cancer (NSCLC)\nEstimated primary completion: 20 April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06907615
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459751-2039@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20300115
DTEND;VALUE=DATE:20300116
SUMMARY:HLX43: Phase 2/3 readout est. (NCT07459751)
DESCRIPTION:HLX43\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A Globa
 l Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43
  Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanc
 ed or Metastatic Squamous Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 15 January 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/hlx43#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07459751
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
